Driven to remain abreast of changes in the field, he aligns himself with the American Chemical Society, the Society for Medicines Research, and the Royal Society of Chemistry.
CHAPEL HILL, NC, January 26, 2024 /24-7PressRelease/ -- Peter Brown has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
A seasoned medicinal chemist with years of professional experience in his field, Dr. Brown excels as the chemical probes guru and project manager for the University of North Carolina at Chapel Hill as part of the Structural Genomics Consortium (SGC). In this capacity, he coordinates chemical probe discovery for the EUbOPEN Project, which focuses on putting chemical probes into the public domain. Additionally, Dr. Brown is responsible for chemical probes for the Toronto Group and coordinates research activities to discover chemical probes for WDR proteins and E3 ligases.
During the early stages of his career, Dr. Brown managed SGC projects between collaborators for various institutions, including GSK, Boehringer Ingelheim, Novartis, Pfizer, Abbott, Takeda, Bayer, JNJ, Merck, the University of North Carolina, Mount Sinai School of Medicine, and the Ontario Institute for Cancer Research. Likewise, Dr. Brown worked as Section Head of medicinal chemistry for GlaxoSmithKline, where he worked alongside Tim Willson studying orphan nuclear receptors. Due to his vast breadth of knowledge, Dr. Brown has contributed to such articles as "Discovery of a Novel DCAF1 Ligand Using a Drug-Target Interaction Prediction Model: Generalizing Machine Learning to New Drug Targets" and "Methylation of the Hippo effector YAP by the methyltransferase SETD7 drives myocardial ischemic injury: A translational study."
Before starting his professional journey, Dr. Brown earned a Bachelor of Science in applied chemistry before completing a PhD in Chemistry at The University of Sheffield. Amidst his doctoral studies, he met Philip Magnus at a scientific meeting at the University of Bangor. Upon graduating with his PhD, Magnus invited him to collaborate on an alkaloid chemistry project for his postdoctoral studies at Indiana University Bloomington, culminating in the total synthesis of pleiomutine, a bis-indole alkaloid. Driven to remain abreast of changes in the field, he aligns himself with the American Chemical Society, the Society for Medicines Research, and the Royal Society of Chemistry. Though hard work and dedication have brought him far in his career, he credits his success to his fascination with the wonders of chemistry. Looking ahead, Dr. Brown intends to ensure the success of an antiviral project.
About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Marquis celebrates its 125th anniversary in 2023, and Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® publications may be visited at the official Marquis Who's Who® website at www.marquiswhoswho.com.
# # #